Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma Inc (NASDAQ: TBPH) drives innovation in organ-selective medicines, with this dedicated news hub providing essential updates for stakeholders. Access verified press releases and objective reporting on clinical developments, regulatory milestones, and strategic partnerships.
This comprehensive resource delivers timely information about TBPH's respiratory therapies like YUPELRI® and emerging pipeline candidates. Track progress across key areas including COPD treatment advancements, neurological disorder research, and collaborative drug development initiatives.
Users can expect updates covering FDA submissions, clinical trial outcomes, financial results, and scientific publications. All content undergoes rigorous verification to ensure alignment with corporate disclosures and regulatory standards.
Bookmark this page for direct access to primary source materials and distilled insights into Theravance Biopharma's progress in biopharmaceutical innovation. Regularly refreshed content supports informed decision-making for investors and industry observers.
Theravance Biopharma (NASDAQ: TBPH) reported a record quarter for YUPELRI® (revefenacin) with Q3 2022 net sales reaching $18.7 million, a 35% increase year-over-year. The company completed a significant transaction selling TRELEGY ELLIPTA royalty rights to Royalty Pharma for $1.1 billion in upfront cash and potential milestones. With a strong cash position of $487 million, Theravance is debt-free and initiated a $250 million capital return program. R&D expenses decreased significantly to $9.9 million, while total revenue for Q3 was $12.5 million.
Theravance Biopharma (NASDAQ: TBPH) announced promising Phase 3 results for its investigational drug, Ampreloxetine, targeting neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Data presented at the 33rd International Symposium on the Autonomic Nervous System shows significant symptom improvement across multiple scales compared to placebo. Ampreloxetine demonstrated a similar safety profile to placebo, with no significant adverse effects. The company plans to initiate a new registrational Phase 3 study in early 2023, aiming to file for NDA with the FDA.
Theravance Biopharma, Inc. (NASDAQ: TBPH) will announce its third quarter 2022 financial results and provide a business update after market close on November 7, 2022. A conference call and webcast will follow at 5:00 pm ET. The company focuses on delivering Medicines that Make a Difference and has developed the FDA-approved YUPELRI inhalation solution for COPD patients. Investors can listen to the live call via Theravance's website and access a replay for 30 days post-event.
Theravance Biopharma (NASDAQ: TBPH) announced new data on ampreloxetine for neurogenic orthostatic hypotension (nOH) to be presented at the 33rd International Symposium on the Autonomic Nervous System, scheduled for November 2-5, 2022, in Maui, Hawaii. The data includes three presentations on November 2, covering a Phase 3 study and the drug's effects on patients with multiple system atrophy (MSA). Ampreloxetine is a norepinephrine reuptake inhibitor aimed at alleviating nOH symptoms, which affect a significant percentage of MSA patients.
Theravance Biopharma (NASDAQ: TBPH) announced a $95 million modified Dutch auction tender offer to repurchase its ordinary shares. The company will buy shares at prices between $9.75 and $10.50 each through November 10, 2022. As of September 27, 2022, there are 67,365,912 shares outstanding. If fully subscribed, the offer could buy approximately 13.4% to 14.5% of outstanding shares. The offer is not contingent on a minimum number of shares being tendered, and will be funded using cash on hand.
Theravance Biopharma (NASDAQ: TBPH) announced a $250 million capital return program, which includes buying GSK's 9.6 million shares at $9.75 each. This acquisition closes on September 20, 2022. The Company will soon launch a Dutch auction tender offer to repurchase approximately $95 million of its ordinary shares, followed by an Open Market Stock Repurchase Plan for an additional $60 million. The capital return aims to enhance shareholder value and is expected to be completed by the end of 2023.
Theravance Biopharma (NASDAQ: TBPH) will participate in two upcoming investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 13 at 11:10 am ET and the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 1:30 pm ET. Both events will be webcast, accessible via Theravance.com. The company focuses on delivering innovative medicines, including the FDA-approved YUPELRI® for COPD. Event replays will be available for 30 days.
Theravance Biopharma (TBPH) reported strong Q2 2022 results with record net sales of YUPELRI® (revefenacin) at $17.2M, up 17% year-over-year. The company is advancing Ampreloxetine towards NDA filing after discussions with the FDA, requiring one additional Phase 3 study. A significant deal involved selling TRELEGY ELLIPTA royalty interests to Royalty Pharma for an upfront cash of $1.1 billion, potentially exceeding $1.5 billion in total value. The company anticipates becoming cash flow positive by the end of 2022.
Theravance Biopharma (NASDAQ: TBPH) will report its Q2 2022 financial results and provide a business update on August 4, 2022, after market close. A conference call will follow at 5:00 pm ET. The call can be accessed via phone or streamed online through the company's website. A replay will be available for 30 days post-call. Theravance is focused on delivering innovative medicines, including its FDA-approved YUPELRI® for COPD management.
Theravance Biopharma (NASDAQ: TBPH) announced a tender offer to purchase all outstanding 3.25% Convertible Senior Notes due 2023, totaling $230 million in aggregate principal. Investors will receive $1,000 for each $1,000 of notes, plus accrued interest, if accepted. The offer expires on August 23, 2022. The company plans to fund the purchase with cash on hand. The offer is subject to certain conditions, and no minimum amount of notes is required to be tendered.
